Researchers in Louisiana report a novel therapeutic strategy to overcome tumor-induced immunosuppression, preserving the ability of T-cells to attack cancer cells.
“Our immune systems are capable of destroying cancer cells, and several approved and experimental drugs stimulate cancer immunity,” says Lucio Miele, MD, PhD, Assistant Dean for Translational Research at LSU Health New Orleans School of Medicine. “But cancers fight back, producing substances that weaken immune cells.”
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
Immune system cells that kill cancer cells are called CD8 T-cells. To be effective, CD8 T-cells need a protein made by the NOTCH1 gene. Miele and colleagues had previously found that adenosine, an immune-suppressive substance released by tumor cells, causes the breakdown of NOTCH1, weakening T-cells.
In the most recent study, published in Frontiers in Immunology, an LSU Health New Orleans research team led by postdoctoral researcher Giulia Monticone, PhD, determined that an enzyme called CBL-B causes the breakdown of NOTCH1 in T-cells. Collaborating with a Massachusetts biotech firm that is developing CBL-B inhibitors, they were able to show that their experimental inhibitors do protect NOTCH1 from breaking down in CD8 T-cells and make them far more effective in killing breast and colorectal cancer cells.
“When added to existing immunotherapeutics, these CBL-B inhibitors greatly increased their potency,” Dr. Miele adds. “This new strategy could expand the efficacy of cancer immunotherapy by making patients' T-cells able to evade the immune-suppressive defenses of tumors.”